Racial and Insurance-related Disparities in Delivery of Immunotherapy-type Compounds in the United States

Vivek Verma, Waqar Haque, Taylor R. Cushman, Chi Lin, Charles B. Simone, Joe Y. Chang, Shearwood McClelland, James W. Welsh

Research output: Contribution to journalArticle

Abstract

Racial and/or socioeconomic factors affect the type of therapies delivered for non-small cell lung cancer (NSCLC). Given the rapid expansion of immunotherapy for NSCLC, it is a crucial public health priority to evaluate disparities in administration thereof. The National Cancer Database (NCDB) was queried for newly diagnosed metastatic NSCLC. Patients were dichotomized based on receipt of immunotherapy-type compounds (ICs) based on NCDB coding. Multivariable logistic regression ascertained factors associated with IC delivery. Subgroup analysis, performed by univariate logistic regression modeling, evaluated the effect of race while stratifying for insurance type. Of 504,447 patients, 11,420 (2.3%) received ICs, and 493,027 (97.7%) did not. From 2004 to 2012, ≤1% of patients received ICs; however, 4.9% did so in 2013, 6.6% in 2014, and 8.7% in 2015. ICs were more likely administered to younger and healthier patients, those living farther from treating facilities, and in more educated areas (P<0.05 for all). ICs were more often delivered to adenocarcinomas, and patients who received chemotherapy but not radiotherapy (P<0.05 for all). In addition to geographic differences, uninsured and Medicaid populations received ICs less often, along with African Americans. On subgroup analysis, African Americans were less likely to receive ICs even when stratified for Medicare, Medicaid, or private insurances. Because IC utilization is expected to amplify even further going forward, these public health and economic issues are essential to identify and address appropriately, and have implications on pharmaceutical/insurance companies, value-based oncology, and public health policy. Methods to address these inequalities are also discussed.

Original languageEnglish (US)
Pages (from-to)55-64
Number of pages10
JournalJournal of Immunotherapy
Volume42
Issue number2
DOIs
StatePublished - Feb 1 2019

Fingerprint

Insurance
Immunotherapy
Non-Small Cell Lung Carcinoma
Public Health
Medicaid
African Americans
Logistic Models
Databases
Health Priorities
Public Policy
Medicare
Health Policy
Neoplasms
Adenocarcinoma
Radiotherapy
Economics
Drug Therapy

Keywords

  • health policy
  • immunotherapy
  • non-small cell lung cancer
  • public health
  • targeted therapy

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology
  • Cancer Research

Cite this

Racial and Insurance-related Disparities in Delivery of Immunotherapy-type Compounds in the United States. / Verma, Vivek; Haque, Waqar; Cushman, Taylor R.; Lin, Chi; Simone, Charles B.; Chang, Joe Y.; McClelland, Shearwood; Welsh, James W.

In: Journal of Immunotherapy, Vol. 42, No. 2, 01.02.2019, p. 55-64.

Research output: Contribution to journalArticle

Verma, V, Haque, W, Cushman, TR, Lin, C, Simone, CB, Chang, JY, McClelland, S & Welsh, JW 2019, 'Racial and Insurance-related Disparities in Delivery of Immunotherapy-type Compounds in the United States', Journal of Immunotherapy, vol. 42, no. 2, pp. 55-64. https://doi.org/10.1097/CJI.0000000000000253
Verma, Vivek ; Haque, Waqar ; Cushman, Taylor R. ; Lin, Chi ; Simone, Charles B. ; Chang, Joe Y. ; McClelland, Shearwood ; Welsh, James W. / Racial and Insurance-related Disparities in Delivery of Immunotherapy-type Compounds in the United States. In: Journal of Immunotherapy. 2019 ; Vol. 42, No. 2. pp. 55-64.
@article{0cae19dba2f34366a3a934058c0b16ab,
title = "Racial and Insurance-related Disparities in Delivery of Immunotherapy-type Compounds in the United States",
abstract = "Racial and/or socioeconomic factors affect the type of therapies delivered for non-small cell lung cancer (NSCLC). Given the rapid expansion of immunotherapy for NSCLC, it is a crucial public health priority to evaluate disparities in administration thereof. The National Cancer Database (NCDB) was queried for newly diagnosed metastatic NSCLC. Patients were dichotomized based on receipt of immunotherapy-type compounds (ICs) based on NCDB coding. Multivariable logistic regression ascertained factors associated with IC delivery. Subgroup analysis, performed by univariate logistic regression modeling, evaluated the effect of race while stratifying for insurance type. Of 504,447 patients, 11,420 (2.3{\%}) received ICs, and 493,027 (97.7{\%}) did not. From 2004 to 2012, ≤1{\%} of patients received ICs; however, 4.9{\%} did so in 2013, 6.6{\%} in 2014, and 8.7{\%} in 2015. ICs were more likely administered to younger and healthier patients, those living farther from treating facilities, and in more educated areas (P<0.05 for all). ICs were more often delivered to adenocarcinomas, and patients who received chemotherapy but not radiotherapy (P<0.05 for all). In addition to geographic differences, uninsured and Medicaid populations received ICs less often, along with African Americans. On subgroup analysis, African Americans were less likely to receive ICs even when stratified for Medicare, Medicaid, or private insurances. Because IC utilization is expected to amplify even further going forward, these public health and economic issues are essential to identify and address appropriately, and have implications on pharmaceutical/insurance companies, value-based oncology, and public health policy. Methods to address these inequalities are also discussed.",
keywords = "health policy, immunotherapy, non-small cell lung cancer, public health, targeted therapy",
author = "Vivek Verma and Waqar Haque and Cushman, {Taylor R.} and Chi Lin and Simone, {Charles B.} and Chang, {Joe Y.} and Shearwood McClelland and Welsh, {James W.}",
year = "2019",
month = "2",
day = "1",
doi = "10.1097/CJI.0000000000000253",
language = "English (US)",
volume = "42",
pages = "55--64",
journal = "Journal of Immunotherapy",
issn = "1524-9557",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Racial and Insurance-related Disparities in Delivery of Immunotherapy-type Compounds in the United States

AU - Verma, Vivek

AU - Haque, Waqar

AU - Cushman, Taylor R.

AU - Lin, Chi

AU - Simone, Charles B.

AU - Chang, Joe Y.

AU - McClelland, Shearwood

AU - Welsh, James W.

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Racial and/or socioeconomic factors affect the type of therapies delivered for non-small cell lung cancer (NSCLC). Given the rapid expansion of immunotherapy for NSCLC, it is a crucial public health priority to evaluate disparities in administration thereof. The National Cancer Database (NCDB) was queried for newly diagnosed metastatic NSCLC. Patients were dichotomized based on receipt of immunotherapy-type compounds (ICs) based on NCDB coding. Multivariable logistic regression ascertained factors associated with IC delivery. Subgroup analysis, performed by univariate logistic regression modeling, evaluated the effect of race while stratifying for insurance type. Of 504,447 patients, 11,420 (2.3%) received ICs, and 493,027 (97.7%) did not. From 2004 to 2012, ≤1% of patients received ICs; however, 4.9% did so in 2013, 6.6% in 2014, and 8.7% in 2015. ICs were more likely administered to younger and healthier patients, those living farther from treating facilities, and in more educated areas (P<0.05 for all). ICs were more often delivered to adenocarcinomas, and patients who received chemotherapy but not radiotherapy (P<0.05 for all). In addition to geographic differences, uninsured and Medicaid populations received ICs less often, along with African Americans. On subgroup analysis, African Americans were less likely to receive ICs even when stratified for Medicare, Medicaid, or private insurances. Because IC utilization is expected to amplify even further going forward, these public health and economic issues are essential to identify and address appropriately, and have implications on pharmaceutical/insurance companies, value-based oncology, and public health policy. Methods to address these inequalities are also discussed.

AB - Racial and/or socioeconomic factors affect the type of therapies delivered for non-small cell lung cancer (NSCLC). Given the rapid expansion of immunotherapy for NSCLC, it is a crucial public health priority to evaluate disparities in administration thereof. The National Cancer Database (NCDB) was queried for newly diagnosed metastatic NSCLC. Patients were dichotomized based on receipt of immunotherapy-type compounds (ICs) based on NCDB coding. Multivariable logistic regression ascertained factors associated with IC delivery. Subgroup analysis, performed by univariate logistic regression modeling, evaluated the effect of race while stratifying for insurance type. Of 504,447 patients, 11,420 (2.3%) received ICs, and 493,027 (97.7%) did not. From 2004 to 2012, ≤1% of patients received ICs; however, 4.9% did so in 2013, 6.6% in 2014, and 8.7% in 2015. ICs were more likely administered to younger and healthier patients, those living farther from treating facilities, and in more educated areas (P<0.05 for all). ICs were more often delivered to adenocarcinomas, and patients who received chemotherapy but not radiotherapy (P<0.05 for all). In addition to geographic differences, uninsured and Medicaid populations received ICs less often, along with African Americans. On subgroup analysis, African Americans were less likely to receive ICs even when stratified for Medicare, Medicaid, or private insurances. Because IC utilization is expected to amplify even further going forward, these public health and economic issues are essential to identify and address appropriately, and have implications on pharmaceutical/insurance companies, value-based oncology, and public health policy. Methods to address these inequalities are also discussed.

KW - health policy

KW - immunotherapy

KW - non-small cell lung cancer

KW - public health

KW - targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85059930103&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059930103&partnerID=8YFLogxK

U2 - 10.1097/CJI.0000000000000253

DO - 10.1097/CJI.0000000000000253

M3 - Article

C2 - 30628924

AN - SCOPUS:85059930103

VL - 42

SP - 55

EP - 64

JO - Journal of Immunotherapy

JF - Journal of Immunotherapy

SN - 1524-9557

IS - 2

ER -